IndraLab

Statements

BAP1 inhibits mastoparan-M. 3 / 3
| 3
sparser
"Based on this model, EZH2 inhibition was tested in BAP1 inactivated MPMs [ xref ]."
34067960
sparser
"The EZH2 inhibitor tazemetostat was administered to patients with BAP1 inactivated MPM (loss of nuclear expression)."
34067960
sparser
"In patients with BAP1-inactivated MPM, the disease control rate was 54% (95% CI: 42–67%; 33 of 61 patients) at week 12 after a median follow-up of 35.9 week; no patients had a confirmed complete response and two patients had a confirmed partial response."
38410609